RxDoctor Payments Data

James Allen, PA

Physician Assistant · Decatur, GANPI 1063036150

Payments from drug & device makers

$3,875in general payments, 2019–2025

Across 223 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$631
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
  • Otsuka America Pharmaceutical, Inc.$521
  • AbbVie$316
  • Corium, LLC$265
  • Neos Therapeutics, LP$168
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,62293%
  • Education$2537%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,875 in reported general payments places this provider in the 85th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$7,160
Medicare patients
21
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine13$137,134
Invega SustennaPaliperidone Palmitate31$99,800
Abilify MaintenaAripiprazole13$35,850
VraylarCariprazine Hcl22$30,569
SpravatoEsketamine Hcl17$25,514
Lurasidone Hcl18$13,088
Paliperidone ErPaliperidone58$4,325
Ramelteon12$3,217
Duloxetine Hcl96$1,779
Divalproex Sodium ErDivalproex Sodium67$1,353
Quetiapine Fumarate135$1,302
Mirtazapine81$1,198
Divalproex Sodium60$977
Alprazolam64$884
Bupropion XlBupropion Hcl49$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$631$137,13413 claims
Johnson & JohnsonInvega Sustenna, Spravato$57$125,31448 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$521$35,85013 claims
AbbVieVraylar$316$30,56922 claims
Almatica Pharma LLCSertraline Hcl$121$32782 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →